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1  | INTRODUC TION
The 58 US organ procurement organizations (OPOs) are not-for-
profit entities with a federal contract to cover a specific geographic 
area over which the OPO is granted exclusive responsibilities, that 
is, a monopoly. Required OPO tasks include assessment of potential 
organ donors, obtaining consent for organ donation from next of 
kin, surgical recovery and preservation of viable organs, and trans-
port of organs to transplant center hospitals. Allocation of any organ 
to a specific recipient is directed through the Organ Procurement 
Transplantation Network (OPTN) and the United Network for Organ 
Sharing (UNOS), which holds the federal contract from the OPTN. 
Transplant center professionals make the final decision to accept and 
transplant or reject and discard any individual organ.
Whereas the costs for most aspects of the organ transplant 
process have been reported,1-3 the functional OPO cost, gener-
ally referred to as the organ acquisition cost (OAC), has not been 
widely researched.4 As a consequence of the National Organ 
Transplantation Act (NOTA),5 OPOs have a defined method of as-
sessing OAC, and the aggregate costs incurred by any OPO are 
unique to that OPO. Because all areas of the United States are the 
responsibility of some OPOs, there are many potential variations in 
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Using 5 years of US organ procurement organization (OPO) data, we determined 
the cost of recovering a viable (ie, transplanted) kidney for each of 51 OPOs. We 
also examined the effects on OPO costs of the recovery of nonviable (ie, discarded) 
kidneys and other OPO metrics. Annual cost reports from 51 independent OPOs 
were used to determine the cost per recovered kidney for each OPO. A quadratic 
regression model was employed to estimate the relationship between the cost of 
kidneys and the number of viable kidneys recovered, as well as other OPO perfor-
mance indicators. The cost of transplanted kidneys at individual OPOs ranged widely 
from $24 000 to $56 000, and the average was $36 000. The cost of a viable kidney 
tended to decline with the number of kidneys procured up to 549 kidneys per year 
and then increase. Of the total 81 401 kidneys recovered, 66 454 were viable and 
14 947 (18.4%) were nonviable. The costs of kidneys varied widely over the OPOs 
studied, and costs were a function of the recovered number of viable and nonviable 
organs, local cost levels, donation after cardiac death, year, and Standardized Donor 
Rate Ratio. Cost increases were 3% per year.
K E Y W O R D S
donors and donation: deceased, economics, ethics and public policy, health services and 
outcomes research, kidney transplantation/nephrology, organ procurement and allocation, 
Organ Procurement and Transplantation Network (OPTN), organ procurement organization, 
organ transplantation in general
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expenses including local labor costs, the number of potential and 
actual donors, the number of transplant hospitals in the OPO service 
area, hospital charges for maintaining donor organ function after 
brain death (prior to organ recovery), and other costs.
Among US OPOs, the number of kidneys recovered annu-
ally varies from fewer than 100 to over 800 kidneys procured and 
transplanted. In this analysis, we have sought to describe variations 
in kidney procurement costs across the United States and differ-
ences in kidney cost by OPO size (hereafter defined by the num-
ber of kidneys procured annually). Kidney acquisition costs related 
to transplanted (viable) organs and of those related to discarded, 
“nonviable” kidneys (ie, organs recovered for transplantation but 
not transplanted) on cost and OPO outcomes were also examined. 
Understanding cost variations among US OPOs could allow for prag-
matic assessments regarding OPO efficiency, economies of scale, 
and other matters related to policy issues affecting OPOs and the 
patients ultimately served.
2  | METHODS AND DATA
2.1 | Data
Of the 58 US OPOs, six are hospital based, and specific OPO cost 
data were not available. Annual cost reports from the remaining 51 
independent OPOs were analyzed with data from Form CMS 216-
946,7 for the 5 years 2013 through 2017. The maximum possible 
OPO annual reports would be 255 (5 years × 51 OPOs); however, 
only 40 reports for 2013 and 48 for 2017 were available resulting 
in a working sample of 241 (95%) OPO annual reports for the study 
period.
Unless noted otherwise, the number of counted kidneys is for 
“viable” organs, which are those kidneys that are ultimately trans-
planted (Worksheet S-1; Part 1, Line 3; Column 3; Form CMS 216-
94; all viable kidneys, local and imported). OPO costs incurred in 
the procurement and sale of tissues are removed by the Centers for 
Medicare and Medicaid Services (CMS) from their general account-
ing system, which focuses exclusively on organs via Worksheet B-1 
and are excluded from this analysis. Organ procurement direct costs 
(eg, hospital charges, surgeon fees etc) are aggregated by organ 
type (kidney, liver, etc) and indirect costs (overhead) are aggregated 
across all organ types and allocated as a linear function of the sum of 
organ counts of all types. When multiple organs are removed from a 
donor, those costs specific to an organ are assigned to the direct cost 
for that organ, whereas other direct costs are divided equally by the 
number of organs from that donor.
Costs were calculated as the total expenses an OPO incurred 
for kidney procurement through delivery to a transplant center. 
These costs included all direct costs as well as allocated indirect 
costs. Total costs for kidney procurement within an OPO were di-
vided by the number of viable kidneys to obtain cost per kidney 
for that OPO and then in the case of the simple mean model aver-
aged for the years of available data with a resulting cost per kidney 
procured for that OPO. In the repeated measures model (which is 
the primary model in this manuscript) the cost data were analyzed 
on a yearly basis.
We adjusted input labor costs by the local price index for each 
OPO headquarters city using the Expatistan8 index, which is a cost 
of living (COL) database comparing cities worldwide. A second ad-
justment of local input costs used the CMS Wage Index9 for the year 
2015 for the county in which the OPO is headquartered.
We examined OPO performance measures including the 
Standardized Donation Rate Ratio (SDRR) as reported for each OPO 
by the Scientific Registry of Transplant Recipients.10 Because there 
is controversy regarding this measure, we also examined donors per 
1000 deaths of patients under 75 years of age who were likely pos-
sible donors (data limited to calendar year 2015) as a potential OPO 
performance measure recognizing the importance of standardized, 
verifiable, and objective metrics of OPO performance.11
2.2 | Statistical analysis
For all OPO years, descriptive statistics for cost of kidneys and po-
tential predictors of cost included the following: number of trans-
planted kidneys, two COL measures, percentage of nonviable 
kidneys, percentage of donation after cardiac death (DCD) donors, 
25th percentile of wait times (in months), number of transplant pro-
grams in the OPO, percentage of donors >65 years of age, SDRR, and 
donors per 1000 deaths under age 75 (year 2015). Two statistical 
models employing linear regression were examined. In model 1, we 
averaged the total cost of kidney acquisitions and number of viable 
kidneys recovered over the 5 years resulting in a single measure of 
cost and a single measure of viable kidney count for each OPO. In 
model 2 we used a repeated measures approach in which we con-
sidered each set of annual OPO data as a separate observation and 
used generalized estimating equations to account for the correlation 
between repeated OPOs, employing a compound symmetry covari-
ance matrix. Results proved robust between the two models, so with 
a few exceptions as noted, only the repeated measures estimates 
(model 2) are reported.
These models examined the relations among selected covariates, 
where cost per kidney was the dependent variable. The independent 
variable of average number of kidneys procured was examined in 
linear, squared, and cubic form, after Dor et al.12 Other covariates in-
cluded percentage of nonviable kidneys, year, percentage of donors 
>65 years of age, measures of wait times, number of transplant pro-
grams in the OPO, and donors per 1000 deaths age less than 75.11 
Models adjusted for local input costs using either the COL index8 or 
the CMS Wage Index.9 Because results were virtually identical with 
either adjustment, estimates are displayed only for the COL index 
adjusted model.
The cost curve of expected cost per kidney by count of kidney 
transplants is displayed unadjusted, adjusted to the mean COL index 
(157.6), and to three levels of percentage of nonviable kidneys (the 
5th percentile, median, and 95th percentile) to display the potential 
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role these variable play in determining cost of a kidney. In effect, this 
estimation adjusted each OPO's cost to the mean (average) of input 
cost levels to allow for comparison as if all OPOs faced the same 
input cost level.
Due to the missing values in 2013 and 2017, we performed a 
sensitivity analysis examining only those OPOs with complete data 
for all 5 years (n = 40) to ensure that results were consistent. No 
meaningful differences were found in this subanalysis.
3  | RESULTS
There is wide variation in costs per organ and the number of viable 
kidneys procured among US OPOs (Table 1). The average cost of 
a transplanted kidney over the 5-year period was $36 027 (range: 
$24 231-$55 995; interquartile range [IQR] was from $31 607 to 
$40 319) and the average number of kidneys transplanted per OPO 
was 274 (range: 48-931; IQR = 127-361) across the 238 OPO-years. 
The number of nonviable kidneys averaged 17.8%. Fifty percent of 
OPOs (using IQR) recovered between 37 (13.5%) and 60 (21.9%) 
nonviable kidneys per year. The average OPO retrieved 44 DCD kid-
neys per year and 50% of OPOs (using IQR) would have retrieved 
between 27 and 58 DCD kidneys annually.
The number of nonviable kidneys procured was positively asso-
ciated (slope = 0.2438 with the number of viable kidneys procured 
(Figure 1), with an R2 = .74, P < .0001). By simple linear regression, 
the model suggests that for every 10 viable kidneys there is an ex-
pectation that 2.4 nonviable kidneys are recovered.
Figure 2 depicts the OPOs with the most and least costly kid-
neys. A total of 13 OPOs reported procurement costs below 
$32 000 and 12 OPOs reported procurement costs above $40 000 
per transplanted kidney. (These statistics are from the simple mean 
for each OPO for the 5 years.) The nine donor service areas with 
the costliest kidneys included Buffalo, NY; North Liberty, IA; San 
Ramon, CA; Honolulu, HI; Los Angeles, CA; Las Vegas, NV; Troy, NY; 
Greenville, NC; and Bloomfield, CT. The seven OPO service areas 
with the least costly kidneys included Tampa, FL; Indianapolis, IN; 
North Charleston, SC; Nashville, TN; Pittsburgh, PA; San Antonio, 
TX; and Philadelphia, PA.
Table 2 presents the basic estimated least squares models with 
the same dependent variable of average cost per viable kidney. 
Mean cost per kidney across OPOs = $36 102, n = 234 The R2 is 
.32 with 237 observations in this repeated measure model clearly 
suggesting a quadratic relationship with the coefficient on the count 
of organs procured and organs squared being substantial and sta-
tistically significant. Addition of a cubic term to a model with linear 
and quadratic terms failed to improve the model fit. The full model 
contains 14 covariates that include a range of measures reporting 
on a series of hypotheses regarding OPO operations. The left side 
of Table 2 presents the results for this full model and the right side 
presents the model limited to the 7 of 14 covariates that passed the 
test of significance at P < .05.13
The results indicate that OPOs in areas of the country with 
higher COL have higher kidney costs (+$94.89 higher cost per kidney 
per 1-unit higher COL, P = .002). OPOs located at the 75th percentile 
of COL would have an average higher cost per kidney of $2087 than 
OPOs at the 25th percentile of COL.
OPOs that retrieved more nonviable kidneys experienced higher 
cost per viable kidney. As shown in Table 2 (right side), in comparing 
OPOs with the same number of procured kidneys, having 1% more 
nonviable kidneys is associated with a $275 higher cost per viable 
kidneys. Comparing the IQR for percentage of nonviable kidneys, 
which is 7.7% (21.2%-13.5%), translates into an increased cost of 
$2121 per viable kidney (ie, comparing an OPO at the 75th percen-
tile of percentage of nonviable vs the 25th percentile of percentage 
of nonviable kidneys).
TA B L E  1   Basic sample/census statistics, organ procurement organization (OPO) unit of observation, 2013-2017a
Variable Mean SD Interquartile range Minimum Maximum
Average kidney count/y/OPO 274 177 127-361 48 931
Average cost per kidney/OPO $36 026 $5989 $31 607-$40 319 $24 231 $55 995
Cost of living in the city where OPO is 
headquartered
157 24 142-164 124 239
Centers for Medicare and Medicaid 
Services Wage Index in the county 
where OPO is headquartered
1.01 0.17 0.90-1.04 0.82 1.71
Nonviable organs (%) 17.8 5.7 13.5-21.2 4.3 39.6
Donation after cardiac death (%) 16.0 8.4 9.9-21.9 0 42.4
25th percentile of wait times (mo) 15.7 8.1 10.4-19.2 4.2 47.5
Transplant programs in the OPO 12.8 8.9 9.0 6-15 42
Donor age >65 (%) 6.3 3.9 3.3-9.1 0 20.2
Standardized donation rate ratio 0.99 0.09 0.95-1.03 0.69 1.40
Donors per 1000 deaths <75 y with 
likely donor possibility (2015 only)11
111 29 93-129 53 199
aCount (n) of OPOs each year: 2013:40, 2014:51, 2015:51, 2016:51, 2017:48: Average model over the 5 y, that is, not the repeated measures model. 
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F I G U R E  1   Correlation between count of viable kidneys and count of nonviable kidneys
F I G U R E  2   Geographic distribution of highest and lowest kidney transplant costs
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OPOs that procure DCD kidneys also have higher cost per via-
ble kidney. As indicated, in Table 2, a 1% increase in DCD kidneys 
procured is correlated with higher cost of $128.53 per viable kid-
ney (P < .001). At 16% average DCD kidneys (Table 1) the impact 
of DCD kidneys would be 16.0 × $128.53 = $2056. At the average 
OPO size of 331 total kidneys (viable and nonviable) procured per 
year, there would be approximately 53 DCD kidneys, which suggests 
that $2056/53 = $39 increase in the average cost per viable kidney 
per DCD kidney.
Using the IQR range of SDR of 0.08 (Table 1) and the estimated 
association between SDR and the cost of a viable kidney of minus 
$95.08 per 0.01 (Table 2) suggests that the difference in cost for a 
viable kidney comparing for IQR for SDR equals $760.64. This means 
that the estimated average cost of a viable kidney for an OPO at the 
25th percentile of SDR (SDR = 0.95) would be $760.64 more than a vi-
able kidney from an OPO at the 75th percentile of SDR (SDR = 1.03).
The procurement cost of a transplanted kidney has become more 
expensive over the 5-year of this study, costing approximately $1078 
(Table 2), more each year (P < .0001). This would suggest at $36 102 
average cost per viable kidney that the inflation rate in procurement 
cost per kidney is approximately 3.0% per year.
Figure 3 displays the quadratic nature of the cost curve in respect 
to the number of kidneys transplanted per OPO-year. The figure 
displays the range of viable kidneys from approximately 50-900 kid-
neys per year. The cost of a kidney declines from the highest esti-
mates for the smallest OPOs to a low point, which ranges between 
500 and 600 transplanted kidneys, depending on adjustments. The 
unadjusted model estimates the highest cost for an OPO with 50 
viable kidneys ($55 995/kidney) to the lowest cost for an OPO with 
272 transplants ($24 289/kidney). In OPOs with >549 transplants, 
costs began to rise with increasing number of transplants, reaching 
a cost of $41 140 for an OPO with 910 transplants. Adjustment for 
COL, percentage of nonviable kidneys, and percentage of DCD do-
nors changed the shape of the curve slightly, moving the lowest cost 
per kidney further to the right (OPOs with more kidney transplants 
per year) and with less cost increase for OPOs with the largest vol-
ume of transplants.
There is a computed minimum cost as related to OPO size derived 
from the estimated quadratic cost parameters (Table 2). Depending 
on the adjustments to the model, the cost minimum occurs between 
500 and 600 viable kidneys per year. The unadjusted model predicts 
a minimum cost at 549 viable kidneys per year at an average cost of 
$33 910.
The model predicts that OPOs that procure more than 549 kid-
neys experience a cost per kidney higher than the minimum; that is, 
the cost curve rises after the minimum. And the model predicts that 
TA B L E  2   Quadratic estimation of the mean cost per kidney procured 2013-2017
OPO measures
Full model Parsimonious modela
β 95% CI P value β 95% CI P value
Kidney count/y (per kidney) −52.63 −73.64 to −31.62 <.0001 −39.71 −57.08 to −22.35 <.0001
(Kidney count/y)2 (per 
kidney)
0.04 0.02 to 0.06 .001 0.03 0.01 to 0.05 .005
Cost of living in the city 
where OPO is based (per 
1 unit)
100.26 24.30 to 176.22 .01 94.89 36.75 to 153.03 .001
Nonviable organs (per 1%) 255.07 132.02 to 378.11 <.0001 274.51 176.39 to 372.63 <.0001
Donation after cardiac death 
(per 1%)
114.07 27.37 to 200.77 .01 128.53 49.75 to 207.32 .001
 Standardized donation rate 
ratio (per 0.01)
−95.23 −163.63 to −26.83 .01 −95.08 −155.81 to −34.35 .002
Year (per year) 1077.86 704.58 to 1451.15 <.0001 1042.16 682.90 to 1401.42 <.0001
25th percentile wait time 
(per mo)
−125.41 −283.94 to 33.12 .12 — — —
Transplant programs (per 1) 196.23 −15.40 to 407.87 .07 — — —
Age >65 y (per 1%) −68.58 −225.64 to 88.48 .39 — — —
Land area (per natural log 
mile2)
392.48 −671.95 to 1456.90 .47 — — —
White donor (per 1%) −45.88 −99.59 to 7.84 .09    
Male donor (per 1%) 34.77 −44.48 to 114.01 .39    
Total kidneys/donor (per 1) −1514.11 −6428.70 to 3400.48 .55    
OPO, organ procurement organization.
aMean cost per kidney across OPOs = $36 102, n = 234; Intercept = −2 068 400, P < .0001. 9/23/19. 
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those OPOs recovering fewer than 549 kidneys annually would also 
experience on average, a cost per kidney higher than the computed 
minimum.
The small squares in Figure 2 are individual OPO-Yr data points. 
The estimated effects of the correction for local labor cost (COL) is 
to shift the minimum cost somewhat to the right (higher procure-
ment levels) and to lower somewhat the increasing cost per average 
kidney recovered beyond the minimum. When an OPO gains entry 
into the 70-80th percentile of OPO size, not only do economies of 
scale disappear, but costs rise.
The total number of kidneys recovered with the intent of trans-
plantation was 81 401, as reported by our dataset. Of these, 66 454 
underwent transplantation and 18.4% (14 947) were discarded (non-
viable). Because donor age is a strong predictor of kidney discard,14 
we examined the effect of donor age on viable and nonviable kid-
neys. There was a correlation between donor age and the percent-
age of nonviable kidneys (0.36, P < .01) and the donors over the age 
of 65 (0.40, P < .01). There was also a correlation with mean num-
ber of viable kidneys) and donors over the age of 65 (0.18, P < .01). 
We found a correlation with the donors per 1000 deaths less than 
75 years for deceased likely to be a donor candidate and the count of 
viable kidneys (0.30, P < .04),11 but not with the SDRR (0.22, P < .09).
4  | DISCUSSION
For decades, OPO cost reports have been filed with and are avail-
able from CMS. Yet, information on OPO costs has generally been 
scant. There are numerous reports focused on procured organs as 
well as performance standards, such as ratios of the number of con-
senting donors to potential donors.15-19 Understanding the expenses 
of organ procurement may shed light on areas in which organ re-
covery might improve in terms of cost and efficiency. The average 
cost per kidney and related measures reported in this analysis are 
based on a robust set of data. Averages were based on 5 years of 
cost data reported from essentially all US non-hospital based, that 
is, independent OPOs.
A current issue in kidney transplantation is the discarded, that is, 
nonviable kidney. Recovery costs for discarded kidneys appear to be 
built into total kidney procurement costs: total viable and nonviable 
organ recovery cost divided by the count of viable organs. In effect 
the costs of nonviable organs (and the cost for the viable organs) are 
distributed over the OPOs' sum of viable organs. Although it is often 
implied that Medicare does not pay for nonviable kidneys, the OPO 
cost forms (Worksheet C) suggest that Medicare does cover OPO 
costs for such organs.
A second issue with regard to nonviable organs is whether they 
may be the result of overzealous procurement policies or some other 
approach to recruiting donors that leads to discard and associated 
procurement costs. Shown in Figure 1 is a plot and statistical fit of 
viable vs nonviable organs at the same OPO. There are 241 obser-
vations (OPOs by year), which yields a definitive fit to the estimated 
line. This fitted line has a slope of 0.24 (P < .0001), which suggests 
that the count of nonviable organs is a reasonably constant fraction 
(or percentage) of the viable organs procured. On average for every 
10 viable procurements the typical OPO will incur 2.4 nonviable kid-
neys. The rather high R2 (.74) for a cross-section model like this is 
noteworthy.
F I G U R E  3   Cost per viable kidney with selected adjustments
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A third issue regarding nonviable kidneys is our suggestion that 
the small cost of nonviable kidneys often receives undue emphasis 
compared with the higher value of viable kidneys. It may be that 
OPOs, in correctly seeking to maximize the number of highly valu-
able viable kidneys, may also inadvertently increase the number of 
nonviables. But the great value to society of the former is much 
larger than the cost of the latter. Earlier research by this team1 has 
shown that the net welfare gain to society from a single viable kid-
ney is about $1.1 million and it saves the taxpayer about $146 000, 
whereas the cost of producing a nonviable kidney is in the neighbor-
hood of only $22 000.
Curves depicted in Figure 3 demonstrate that the computed 
cost per kidney generally follows a quadratic relationship between 
average cost per kidney and OPO size. The solid black curve is un-
adjusted by any other covariate. The other curves reflect the basic 
relationship to size adjusted by different covariates. The curve la-
beled adjusted for COL generally has little impact in the smaller sizes 
of the OPO and in the higher ranges of sizes pulls the unadjusted 
curve downward. This suggests that larger OPOs to the right of the 
minimum when adjusted for the COL have lower cost when consid-
ering the local price levels they face. The three remaining adjusted 
lines make adjustment for 3 levels of 2 measures of DCD kidneys 
procured and percentage of nonviable kidneys procured. The three 
levels of the two selected covariates are 5th percentile, median 
(50th percentile), and the 95th percentile. The patterns of the 3 ad-
justed lines suggest that higher proportions of DCD and nonviable 
kidneys raise cost.
The estimated coefficient from (Table 2) of $94.89 (P < .002) 
per one unit on the COL scale indicates that the difference 
across the IQR of 22 points on the COL index is associated with 
22 × $94.89 = $2088 on the average price per viable kidney. At the 
overall mean of $36 102 for price per viable kidney, this IQR spread 
would represent a difference of 6% in the average cost per viable 
kidney. Although this result is quite precise with very narrow uncer-
tainties about estimated parameters, one might observe that COL 
differences across OPOs do not explain much of the difference in the 
cost per kidneys across OPOs. Figure 1, for example, clearly shows 
a 100% difference in the OPO reported cost per kidney. Certainly, 
COL is clearly a factor in the cost structure of OPO costs but not a 
very dominant factor.
The cost of organ procurement is relevant to transplant center 
operations and the relationships that transplant center surgeons 
and physicians cultivate with the local OPO. Englesbe et al18 ex-
plain the importance of organ acquisition costs and how clinically 
oriented physicians and surgeons may benefit from an understand-
ing of transplant center finances. Clinicians should be interested in 
procuring more organs at lower cost and gaining knowledge about 
reasonable acquisition costs. An example may be billing acquisition 
costs in the Kidney Paired Exchange program19 in the circumstances 
of which harbor elements important to both clinical transplantation 
and its financial foundation. In addition, OPO revenue may be ear-
marked to address problems shared by donors and recipients, such 
as quality improvement in organ preservation.
4.1 | Limitations of the study
We were unable to assess the quality of kidneys procured by the 
OPOs, although all viable kidneys in the analysis were not only pro-
cured but were actually transplanted. Although OPO size, local input 
prices, nonviable organs (18.4%), DCD organs (16%), and year were 
addressed in determining procurement costs, there are undoubtedly 
many other contributing factors that simply cannot be fully defined. 
These include specific geographic characteristics, because any OPO 
is, by regulation, responsible for a defined geographic area. Thus, the 
volume and type of potential donor deaths and characteristics of the 
general population as well as other variables may not be measurable 
in an analysis such as ours. Labor costs are 50% of organ procure-
ment expenses, and there is wide variability in labor costs across 
the United States;9 therefore, it is unclear why COL measures do 
not explain a larger fraction of the variation in procurement costs 
across OPOs.
We have conducted many quality checks regarding data in the 
original cost forms, and we have considered the possibility that there 
may be some double counting of viable kidneys due to transfer of or-
gans among OPOs. Conversations with informed OPO professionals 
have not affirmed such a possibility. If, however, double counting of 
viable kidneys is extant, cost estimates per kidney presented in this 
paper would be biased low. In Appendix S1 we attempt to further 
explore this matter.
5  | CONCLUSIONS
Every OPO in the United States is required by CMS to file com-
prehensive cost reports each year. These reports contain exten-
sive cost detail and provide substantial information on organs and 
tissue recovered from deceased donors. These data sources can 
yield useful information when subjected to common analytical 
methods.
We conclude that costs per deceased donor kidney vary con-
siderably over the 51 independent OPOs included in our analysis, 
with the highest cost OPOs almost twice as costly as the lowest. 
Much of this variation in cost is related to the size of operations. 
In addition, our results confirm that COL does affect cost but only 
in a modest manner. Other factors shown to affect cost include 
procurement of nonviable organs, DCD kidneys, and year. We 
tested a long series of hypotheses in which the null hypothesis 
of no relationship could not be rejected. In spite of failure to pass 
the P test these results sill contributed insight into the functions 
of OPOs.
Many other exact sources of cost variance have yet to be deter-
mined. Possible inefficiencies in the current OPO structure might be 
mitigated by consolidating smaller programs and assessing growth of 
larger ones ie larger OPOs are frequently operating in the rising cost 
sector of results. Understanding the reasons for these inefficiencies 
may help to model more efficient and less costly systems for pro-
curement of donor kidneys and other solid organs.
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a limited set of data for 1 year.
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